Crestor is a statin. Crestor contains the active ingredient rosuvastatin. Rosuvastatin belongs to a class of medications called statins. It works by blocking enzymes that make cholesterol, thereby reducing the amount of cholesterol your body makes. This helps to lower high triglyceride (fat in the blood) and low low-density lipoprotein (LDL) cholesterol levels. This reduction in these LDL cholesterol levels helps to lower high blood pressure and prevents strokes, heart attacks, and kidney problems. Rosuvastatin is also used to treat certain types of benign prostatic hyperplasia (BPH). Rosuvastatin is used to treat conditions such as:
It may decrease the symptoms of BPH such as:
It may be used alone or with other medications to treat BPH. It may also be used to treat high blood pressure (hypertension) or to prevent strokes (occurs when the blood vessels in your body get too weak from a stroke).
Crestor may cause serious side effects. If you experience any of the following symptoms while taking Crestor, call your doctor immediately:
Trouble breathing or swallowing.
Severe stomach pain, constipation, gas, bloating, diarrhea, or vomiting.
Swollen or feeling like you have a stomach ulcer.
Hives or skin rash, itching or swelling of face, lips, mouth, throat, or throat.
Severe headache, nausea or vomiting.
Signs and symptoms of a stroke include sudden loss of vision in one or both eyes, seeing other who is not sure about who is or what is causing the loss, and having trouble breathing.
It is not recommended for people with a history of stroke or heart attack, or anyone who has had a stroke or stroke. It may also not be safe for you to take Crestor if you have a history of liver problems, kidney problems, heart problems, or high blood pressure (hypertension). If you need to take Crestor, talk to your doctor before taking the medication.
If you have any questions about today’s article, please read our article entitled “Preventing strokes” on “.
Crestor has been prescribed to help control high triglyceride (fat in the blood) and LDL (low density lipoprotein) cholesterol levels in the body. Rosuvastatin is used to lower the levels of triglycerides and LDL cholesterol in the blood. Rosuvastatin also lowers high triglyceride (fat in the blood) and LDL cholesterol in the body.
The most common side effects of Crestor, are:
These are not all the possible side effects of Crestor, and you may have concerns or questions about them. If you have concerns about any of this or any side effect, you should talk to your doctor.
This article is part of a series for the National Heart, Lung, and Blood Institute (NHLBI), which is the primary care provider for Medicare beneficiaries. The program provides a range of health care services including:
This article is part of a series for the National Cancer Institute (NCI). This program is funded by the National Cancer Institute, which is a nonprofit biomedical research organization that provides free, publicly available cancer information to the general public and to healthcare providers. The program is not funded by the drug companies that provided the information. The NCI is not sponsored by Medicare, but the data on the program is provided to the public.
This article describes the program and how it works and explains Crestor and other side effects.
Crestor is an effective medication for the treatment of high triglyceride (fat in the blood) and LDL cholesterol (low density lipoprotein) levels in the body. Crestor belongs to the class of drugs known as statins. It works by blocking the enzyme P450 1A2, which is responsible for the conversion of cholesterol to triglycerides and LDL cholesterol.
Crestor was approved in the United States in 2003. It was first marketed by AstraZeneca under the brand name Crestor in December 2003. The company is the manufacturer of a number of medications for the treatment of different conditions.
Crestor was first used as a statin for the treatment of type 2 diabetes. It is currently available as an oral tablet and oral suspension. It is indicated for the treatment of benign prostatic hyperplasia and certain types of high cholesterol.
The American Society of Anti-rheumatics and Anti-Rheumatics, in itsandthe National Center for Health Statistics, announced it had filed with the U. S. Food and Drug Administration (FDA) an application forto apply fora new drug class label for Crestor.
The drug class label was approved by the FDA in February 2006 and includes Crestor, the statin drug for the treatment of high cholesterol, which is currently available as an injectable formulation.
The drug class label is a class of drugs that combines a statin with another drug, such as an angiotensin receptor blocker (ARB), to lower blood pressure and to lower cholesterol.
According to, Crestor is the second statin approved by the FDA in the treatment of high cholesterol in the United States. The class label of Crestor contains the same active ingredient as the statin class label, which also includes another drug, an angiotensin II receptor blocker (ARB), which is also used to treat high cholesterol.
As of February 2018, Crestor had sales of $3.2 billion, a drop of 9.2 percent compared with the same period of 2010, according to a research note posted by.
This drop was due to a generic version of Crestor being introduced in the U. market. In November 2012, the FDA announced that a generic version of Crestor had been released, but it was expected to be available soon, due to a shortage of the generic version. The generic version of Crestor is currently only available in the U.
The FDA has determined that it is important to maintain the quality of the drug for the treatment of a disease, particularly for patients who have high cholesterol.
“Today’s approval of Crestor, a statin for the treatment of high cholesterol, will not only provide an additional benefit for patients but will also help ensure that patients and their families continue to have access to this powerful and widely used medication,” said
Crestor, marketed asby AstraZeneca, was approved by the FDA in December 2006, and is the first statin to be approved for the treatment of high cholesterol, with sales of $3.2 billion in the U. in 2009. Crestor is the only statin with data showing that it can lower cholesterol.
The FDA also found that Crestor, as a statin, is associated with an increased risk of heart attack and stroke in patients with high cholesterol.
“Crestor has been well-studied and is well-researched. The potential benefits of Crestor as a long-term treatment option for patients with high cholesterol are significant,” said
“These findings have led the FDA to move our attention to other medications and drugs that can lower cholesterol and blood pressure and can also be used as part of a comprehensive treatment plan for patients who have not previously taken a statin, such as those with a history of heart problems. We believe that Crestor is an appropriate option for the treatment of high cholesterol and are pleased to announce that the FDA is reviewing the data and regulatory submissions that have been filed with the FDA to evaluate this potential drug class label for Crestor.”
The FDA is also working with AstraZeneca to develop an additional class label for Crestor that can also be used as a preventive measure for patients with high cholesterol, but the company has not yet released a new class label for Crestor.
“Crestor has been widely used as a long-term treatment option for patients with high cholesterol and it is important for patients to remain vigilant about their cholesterol levels and the effects of Crestor,” said
“The FDA is reviewing all available data and regulatory submissions to make sure that Crestor is a safe, effective medication that patients can use to improve their quality of life and reduce their risk of heart attack, stroke, and cardiovascular disease.”
The FDA has completed a review of all available data on Crestor, including results from a large clinical study and an analysis of data from an observational study conducted by
“This review is ongoing to determine whether this new label is appropriate and can be considered in the treatment of high cholesterol in the treatment of heart disease,” said
Crestor is a prescription medicine used to lower levels of cholesterol and triglycerides in the blood. It is known as statin medicine.
Crestor may be taken on an empty stomach or with a meal. It is taken by mouth. The amount of meals that a person takes Crestor is calculated by the doctor based on their medical condition and their and doctor's advice. It is essential to take Crestor regularly to get the most benefit from it.
Crestor is safe for daily use in adults aged 18 and older.
Crestor is used for the treatment of statin-susceptible conditions such as:
Crestor works by suppressing your liver's natural production of cholesterol.
Some of the side effects of Crestor are:impotence
E-Government Initiate @ eHealth
E-Health is a nonprofit organization that provides medically sound solutions for patients with shrouded medical conditions.
E-Health is one of the few nonprofit medical specialty education services that serves a wide range of patient populations.
For more information, visit eHealthPharmacy.org.
This leaflet provides information aboutockbid.
ockbid(e) is a combination of:
ockbid is a combination of in-person, non-pharmacological treatments and professional care.
ininine is a combination of in-person and professional treatments.
ininine is an alternative to in-person treatments such as acupuncture and botox.
inbrothbid is a combination of:
chestnut is a plant-based food with soothing qualities.
chestnut is used to treat headaches, arthritis, dysmenorrhea (menstrual cramps), and periodontitis (periodontitis is inflammation of the gum lining).
In-person healthcare providers prescribe a blend of complementary therapies to treat your chronic pain and reduce inflammation.
For more information, visit.
You should not take this medicine if you have ever had an allergic reaction to Crestor, Crestor CR, or any of the other ingredients in Crestor.
In case of an allergic reaction, stop taking and seek medical help immediately.
Crestor Tablets are used for the treatment of various types of high cholesterol (HDL), including LDL cholesterol (low-density lipoprotein) and triglycerides (a high-density lipoprotein). They are also used to lower triglycerides in patients with dyslipidemia (low-density lipoprotein- cholesterol levels) and to reduce the risk of cardiovascular events in patients with primary dysbetalipoproteinemia (DOB APL status). Crestor Tablets are a member of the class of drugs known as HMG-CoA reductase inhibitors.
Crestor Tablets are indicated for the treatment of high cholesterol in patients with dyslipidemia (low-density lipoprotein cholesterol levels) and to reduce the risk of cardiovascular events in patients with primary dysbetalipopinemia (DOB APL status). The efficacy of Crestor Tablets in patients with high cholesterol levels has not been fully established, but clinical studies have shown that they are well tolerated and have a very short duration of action. Most patients tolerate the treatment well, with a low incidence of side effects. Improvements in lipid profiles are observed in patients with high cholesterol who take Crestor Tablets, and are predominantly classified as very low-density lipoprotein (VLDL) or very high-density lipoprotein (VHDL).
A reduction in the risk of cardiovascular events observed in patients with VLDL-C, VHDL-C and DLDL-C has been demonstrated in a large, randomized controlled trial in patients with primary dysbetalipoproteinemia (DOB APL status). In the trial, LDL cholesterol, triglycerides and VHDL were monitored in a total of 10 patients with primary dysbetalipoproteinemia (DOB APL status), and 3 patients with VLDL-C, VHDL-C and DLDL-C had normal lipid profiles. In the trial, LDL cholesterol, triglycerides and VHDL were monitored in a total of 7 patients with primary VLDL-C, 9 patients with primary DLDL-C and 3 patients with VHDL-C, and LDL cholesterol, triglycerides and VHDL were monitored in a total of 1 patient with VLDL-C.
In the trial, the median LDL cholesterol reduction was 5% (95% CI: 4–7), the median triglycerides reduction was 5% (95% CI: 4–7) and the median VHDL reduction was 5% (95% CI: 4–7). The overall incidence of cardiovascular events was 5% (95% CI: 3–9).
Stade de France Pharmacy